Search...
Key facts: Novartis to Acquire Avidity for $12B; Raises Sales Guidance
I'm PortAI, I can summarize articles.
Novartis plans to acquire Avidity Biosciences for $12 billion to enhance its portfolio with muscle-disorder treatment candidates, addressing declining sales from established products such as Entresto.1Novartis has increased its peak sales guidance for KISQALI from over USD 8 billion to over USD 10 billion, and for SCEMBLIX from over USD 3 billion to over USD 4 billion.2Novartis is focusing on strategic mergers and acquisitions, global expansion, and launch excellence as key components of its growth strategy.3
- Novartis plans to acquire Avidity Biosciences for $12 billion to enhance its portfolio with muscle-disorder treatment candidates, addressing declining sales from established products such as Entresto.1
- Novartis has increased its peak sales guidance for KISQALI from over USD 8 billion to over USD 10 billion, and for SCEMBLIX from over USD 3 billion to over USD 4 billion.2
- Novartis is focusing on strategic mergers and acquisitions, global expansion, and launch excellence as key components of its growth strategy.3
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments